Yorclinic

Start Date End Date Funded Value Relevance

CSV

25 50 100

£615,661

Apr 12 - Nov 16

TAILoR (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a Strategy for the Reduction of Insulin Resistance in HIV-Positive Individuals on Combination Antiretroviral Therapy (cART)

MRC award to University of Liverpool

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}